Topline results from Seagen Inc. /Astellas Pharma, Inc.’s Phase Ib/II EV-103 trial of Padcev (enfortumab vedotin-ejfv) and Merck & Co., Inc.’s Keytruda (pembrolizumab) in first-line unresectable locally advanced or metastatic urothelial cancer may help bolster investor enthusiasm around the alleged efforts by Merck to buy Seagen. The results themselves look incrementally positive, but it is likely more data will need to come out to provide a sense of how the results might affect practice.
Padcev/Keytruda Results Could Sweeten Potential Seagen/Merck Deal
Most Observers Still Want More Detailed Data From Urothelial Cancer Study
Seagen/Astellas announced Phase Ib/II trial data for the combination that could lead to an accelerated approval for the antibody-drug conjugate in first-line bladder cancer.
More from Deals
• By
Deal Snapshot: Lilly is the third company to sign a licensing deal for STAC-BBB with Sangamo, which also aims to secure a deal for its Fabry disease program in the second quarter.
• By
AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.
More from Business
• By
The US FDA approved anti-CD19 antibody Uplizna, from Amgen’s $27.8bn purchase of Horizon in 2023, for IgG4-related disease – a larger market than its original NMOSD indication.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.